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ABSTRACT
The prevalence of asthma has been increasing in
Japan, like in other parts of the world. Asthma man-
agement guidelines were developed in Japan in 1993
and 1998. These guidelines have been shown to con-
tribute to the improvement of asthma management in
Japan. Most allergists know the guidelines and make
use of them. However, only half the non-specialists
surveyed knew the guidelines in 1996–97, although
the awareness of the guidelines increased over the
next 3 years. Further efforts are required to implement
the guidelines widely.
Key words: asthma, epidemiology, management
guidelines.
INTRODUCTION
Around the end of the 1980s, many committees and con-
ferences met to develop guidelines for the management
of asthma. All were responding to the realization that the
prevalence and morbidity of asthma had been increasing
in most parts of the world and that deaths from asthma
had increased in some countries but had not decreased
in most countries. More importantly, asthma has been
recognized as a chronic inflammatory disease of the
airway instead of a lung disease with transient episodes
of bronchoconstriction. As in other parts of the world, in
Japan two asthma management guidelines were pub-
lished in 1993 and 1998.1–12
Reed13 described the changes of the management of
asthma as follows:
‘Revolutionary’ is not too strong a term to describe
the change in the understanding of the nature of
asthma and its pathogenesis. ‘Revolutionary’ is also
appropriate to describe the recent change in the
philosophy of treatment, which comes partly from
better understanding of the biology of asthma and
partly from behavioral science, which places 
emphasis not on the process of some arbitrary
regime, but on the outcome, controlling the disease,
and which places the primary responsibility for
achieving this control with the patient. With these
changes, the physician’s task is not only to diagnose
the disease and its severity, to identify the provoking
factors and to recommend treatment but, equally
important, to teach the patient how to control the
symptoms, prevent acute episodes, be physically
active and lead a normal life.
In Japan, around the middle of 1980s, airway inflam-
mation of asthma patients attracted the interest of
researchers in this field. It has long been known that the
airway of asthma patients has characteristic infiltration of
eosinophils and round mononuclear cells. Although the
role of the eosinophils is not conclusively established,
eosinophils have been shown to be proinflammatory cells
in the airway of asthma patients and mononuclear T
helper (Th) 2 lymphocytes upregulate the functions of
eosinophils.14 This airway inflammation induces persis-
tent airway narrowing due to airway remodeling.15,16
The present review is intended to show: (i) the epidemio-
logy of asthma; (ii) the outline of the Asthma Prevention
and Management Guidelines 1998; (iii) recognition and
utilization of the guidelines; and (iv) the effects of the
guidelines.
EPIDEMIOLOGY OF ASTHMA IN JAPAN
Asthma is one of the most common chronic diseases
worldwide and its prevalence is increasing in chil-
dren.17,18 The increase in prevalence of asthma may be
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related to environmental factors, including increasing
exposure to allergens and pollutants in the air.19,20 Asthma
can impair quality of life and be a major cause of
absence from school and work. Data on asthma inci-
dence, morbidity, hospitalization and mortality are needed
to show the extent of the need and efficacy of asthma
management guidelines.
Prevalence of childhood asthma in Japan
Thirty years ago, asthma affected approximately 1% of
children, while the current prevalence of childhood
asthma is approximately 6%. The relationship between
asthma and the environment first began to be considered
in the last half of the 1960s, which has led to differences
in regionally reported asthma prevalence.17
In Kita-Kyushu-shi, asthma prevalence surveys was
performed for 20 years by using the same survey protocol
and at the same regional elementary schools. The survey
showed that the prevalence of asthma increased progres-
sively: in 1971 it was 1.71%, in 1981 it was 3.62% and
in 1991 it was 5.37%.18
Prevalence of adult asthma in Japan
Various surveys have also been conducted in target
groups of adults, such as students or residents of a local
community. These surveys have shown no remarkable
increase over time in asthma prevalence among adults.
Reported prevalence rates have ranged from approxi-
mately 1 to 4%.
In Fujieda, Shizuoka, a group of 12 562 residents,
aged 15 years and older, were surveyed out of a popula-
tion of approximately 110 000 residents in the area and
a second confirming investigation was performed. In
these residents, there were 265 patients with asthma and
48 people with symptoms strongly suggesting asthma as
a complication of chronic obstructive pulmonary disease.
The asthma prevalence for this city was finally calculated
as 3.14%.19
Surveys throughout Japan
Another survey in 24 districts throughout Japan was con-
ducted on people, including those who had undergone
health screening examinations at regional health centers,
and compulsory school age children and their families.
The total number of people surveyed was 8441 children
and 11 495 adults. Diagnosis was based on American
Thoracic Society for Division of Lung Diseases (ATS-DLD)
established criteria. The results of these surveys showed
that:
1. The prevalence of childhood current asthma through-
out Japan was 4.0%. Cumulative prevalence was 6.4%
when patients with a past history of asthma were also
included.
2. Throughout Japan, asthma prevalence in adults
varied by age group. The prevalence was 4.0% in sub-
jects aged 16–19 years, 2.8% in subjects aged 20–29
years, 2.3% in subjects aged 30–39 years and 1.8% in
subjects aged 40–49 years. The cumulative prevalence
for all adults was 3.0% when patients with a past history
of asthma were also included. The cumulative prevalence
for adults aged 15–30 years was 6.2%.20
Asthma deaths in adults
Approximately 5800–6200 adult asthma patients die in
Japan every year. This number has tended to decrease
over the years. Asthma deaths showed a tendency to
increase in the 5–34-year-old age group around 1990,
with a particularly notable increase among males in aged
in their 20s.21
Surveys in hospitals showed that 19% of reported
asthma deaths were considered sudden asthma deaths,
occuring within 1 h after onset of an asthma attack. This
figure increases to 33% when sudden asthma death was
defined as death within 3 h after the onset of the attack.
Most asthma deaths occurred in patients with a chronic
history of severe asthma, but recent surveys have also
shown an increasing incidence of asthma deaths among
patients with a past history of only mild to moderate
symptoms.22
Possible trigger factors responsible for fatal attacks
include respiratory tract infections, emotional stress, over-
work, tapering doses or discontinuation of corticosteroids,
the use of non-steroidal analgesic–antipyretic drugs 
(e.g. aspirin), overdoses of inhaled β2-adrenoceptor 
agonists by metered dose inhaler (MDI) and the use of
beta-blockers.22,23
Asthma deaths in children
The asthma death rate in among children aged 0–4 years
began to decrease steadily in the 1950s and has now
remained at nearly the same level since 1987. The
asthma death rate in patients aged 15–19 years began 
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to slowly rise in 1980, increased considerably in 1985
and peaked around 1990. This increase was especially
noticeable in males. However, this asthma death rate has
been decreasing since 1997. An increasing number of
asthma deaths are now occuring among children with a
previous history of only mild to moderate symptoms. Of
childhood asthma deaths in 1995, 22.5% occurred in
children with a previous history of mild asthma, 23.6%
occurred in children with a history of moderate asthma
and 32.6% occurred in children with a history of severe
asthma.24,25
Sudden unexpected exacerbation of symptoms and
delays in receiving appropriate medical care are associ-
ated with asthma deaths. Factors that contribute to delays
in seeking medical care include judgment errors by the
patient or family regarding the severity of an asthma
attack and overdependency on the use of inhaled β2-
adrenoceptor agonists with an MDI. Another common
problem in adolescent patients with asthma is low compli-
ance with medications and other healthcare instructions.26
OUTLINE OF ASTHMA PREVENTION AND
MANAGEMENT GUIDELINES 1998 IN JAPAN
(JGL98)
In 1993, the Guidelines of Diagnosis and Management
of Asthma by Japanese Society of Allergology (JGL1993)
was released and these guidelines were revised in 1995.
In 1998, the Asthma Prevention and Management
Guidelines were drawn up by a research group sup-
ported by the Ministry of Health and Welfare Project
(JGL1998).11,12 The JGL1998 was developed by updat-
ing JGL1993.
Definition of asthma
The definition of asthma is an important part of these
guidelines, because not only the diagnosis but also the
management approach is based on the understanding of
asthma.
The definition of adult asthma is as follows:
Asthma is characterized by airway inflammation and
varying degrees of airflow limitation, accompanied
by recurrent episodes of coughing, wheezing and
dyspnea. Airflow limitation may range from slight to
life-threatening in severity and at least partially
reversible either spontaneously or with treatment.
Infiltration of large number of inflammatory cells,
including eosinophils, T cells (Th2) and mast cells,
contributes to airway inflammation. There is also
notable injury to the airway mucosal epithelium. In
patients with chronic disease, airflow limitation tends
to become less reversible and it is common to see
evidence of airway remodeling including thickening
of the airway epithelial basement membrane. In 
sensitive patients, airway inflammation and airway
remodeling are associated with airway 
hyperresponsiveness.12
The definition in JGL98 is updated from JGL93 by
adding the concept of airway remodeling. Airway remod-
eling has been recognized to be typical to chronic asthma
and to contribute to persistent airway narrowing and the
increase of airway hyperresponsiveness. Several studies
have shown that inhaled corticosteroids can or may
reverse or prevent airway remodeling.15,16
Key points in management
The key points of JGL1998 are as follows:
1. Asthma is a chronic disorder of the airway. This airway
inflammation is thought to cause recurrent episodes of
symptoms, variable airflow limitation, airway remodeling
and airway hyperresponsiveness. Recently, airway remod-
eling is stressed to be another major cause of persistent
airway narrowing and airway hyperresponsiveness. The
most basic management is to prevent this inflammation
by eliminating the causal factors, including allergens and
air pollution.
2. Asthma is a chronic disease. Asthma can be effec-
tively controlled in most patients, although frequently it
cannot be cured.
3. The major causes of morbidity and mortality are
underdiagnosis and inappropriate treatment.
4. The goals of management are: (i) to enable patients
to enjoy a normal life, comparable to that of healthy
people, and to maintain normal growth and development;
(ii) to maintain respiratory function as close to normal as
possible (i.e. daily peak expiratory flow (PEF) variation
< 10% and PEF at least 80% of predicted values); (iii) to
prevent nocturnal and early morning cough and dyspnea
so that the patient can sleep well; (iv) to prevent asthma
attacks; (v) to reduce the probability of asthma-related
death; and (vi) to minimize adverse re-actions from
asthma medications.
5. Effective control of asthma can be accomplished by
an asthma management program as follows: (i) educate
patients to develop a partnership in asthma manage-
ment; (ii) assess and monitor asthma severity with both
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symptom reports and lung function measurement, includ-
ing PEF or forced expiratory volume in 1 s (FEV1.0); (iii)
avoid or control asthma triggers; (iv) establish individual
medication plans for long-term management; (v) estab-
lish plans for managing acute exacerbations; (vi) the
choice of management should be guided by the severity
of the patient’s asthma and the patient’s life-style; (vii) a
step-wise approach to pharmacologic therapy is sched-
uled following the severity of asthma, and a combination
of anitinflammatory and bronchodilating agents can 
give the best control of asthma; (viii) traditional Kanpo
(Japanese formulations of traditional Chinese herbal
medicines) medicines can be considered as complemen-
tary medications; and (ix) asthma management guidelines
should be used as references to establish an asthma
treatment plan for each patients by physicians.
PHARMACOLOGIC MANAGEMENT
Pharmacologic treatment for long-term 
management of asthma
Drugs
Antiasthma drugs can be divided into two broad 
categories: controller medications (drugs used for the
long-term management of asthma) and reliever medica-
tions (drugs used for relieving acute asthma attacks).
Controller medications Controller medications (con-
trollers) can be broadly classified into two categories,
namely anti-inflammatory drugs and long-acting bron-
chodilators. The most potent anti-inflammatory controller
medications are inhaled or oral corticosteroids. Other
controller drugs include antiallergic agents, such as
leukotriene receptor antagonists, mediator release
inhibitors, histamine H1 receptor antagonists, thrombox-
ane A2 synthase inhibitors and receptor antagonists and
Th2 cytokine inhibitors. Sustained-release theophylline
has anti-inflammatory effects.
Long-acting β2-adrenoceptor agonists and sustained-
release theophylline are generally used as long-acting
bronchodilators.
Kampo medications have a long tradition of use in the
treatment of asthma. In general, asthma symptoms during
the acute stage should be treated with Kampo formula-
tions of the Mao type (e.g. Sho-seiryu-to), while treatment
during the chronic stage should focus on Saiko-type 
formulations, which build up the patient’s constitution 
(e.g. Saiboku-to).
Step-wise approach to long-term pharmacologic man-
agement of asthma
There are four steps of pharmacologic therapy recom-
mended, depending on the severity of the asthma.
Step 1: Mild intermittent asthma This step is indicated
for patients with intermittent mild episodes of asthma and
baseline pretreatment PEF of 80% or greater of predicted
values and diurnal PEF variations of less than 20%.
Treatment is by inhaled or oral β2-adrenoceptor ago-
nists or short-acting theophylline, as needed, during active
symptoms. Inhaled disodium cromoglycate (DSCG) or β2-
adrenoceptor agonists may be taken before physical
activity if needed.
Antiallergic agents or low-dose inhaled corticosteroids
may also be considered.
Step 2: Mild persistent asthma This step is indicated for
patients with more frequent mild asthma symptoms,
including a baseline pretreatment PEF of 70–80% of their
personal best or predicted values and diurnal PEF varia-
tions of 20–30%. 
Treatment includes low doses of inhaled corticosteroids
(beclomethasone dipropionate (BDP) at 200–400 µg/day
or an equivalent dose of fluticasone (FT)), slow-release
theophylline and/or leukotriene antagonists or other anti-
allergic agents. Long-acting β2-adrenoceptor agonists
may be administered to control nocturnal or morning
symptoms.
Step 3: Moderate persistent asthma This step is indi-
cated for patients with nocturnal symptoms and some
limitation in their daily activities at least once per week
and almost daily symptoms of asthma. In addition,
patients may exhibit baseline pretreatment PEF of 60–70%
of their personal best or predicted values and diurnal PEF
variations of greater than 30%.
Treatment includes medium doses of inhaled cortico-
steroids (BDP: 400–800 µg or an equivalent dose of FT),
slow-release theophylline and long-acting β2-adrenoceptor
agonists and/or leukotriene antagonists. Other antiallergic
agents or anticholinergics can be considered.
Step 4: Severe persistent asthma Patients with severe
persistent asthma often require the administration of high
doses of inhaled corticosteroids and/or oral corticos-
teroids and bronchodilator therapy to control their
symptoms. These patients may exhibit a baseline pre-
treatment PEF less than 60% of their personal best or
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predicted values and diurnal PEF variations of greater
than 30%.
Treatment includes high doses of inhaled corticos-
teroids (BDP 800–1600 µg/day or equivalent dose of
FT), slow-release theophylline and long-acting β2-
adrenoceptor agonists. Oral corticosteroids may be
required.
Pharmacologic treatment of acute 
exacerbation
Standard drugs used for the treatment of asthma attacks
(reliever medications) include β2-adrenoceptor agonists
(inhaled, oral, parenteral and taped), theophylline (intra-
venous and oral) and corticosteroids (intravenous and
oral).
A step-wise approach to pharmacologic treatment is
recommended.
Patients with mild symptoms (mild attacks)
Mild dyspnea is present, but the patient can assume a
recumbent position and daily activities are not restricted.
The PEF after bronchodilator use is 70–80% of predicted
value.
Treatment The patient should be treated with a β2-
adrenoceptor agonist inhaled via MDI or nebulizer. If the
patient’s symptoms improve and remain stable without
further treatment for 60 min and if there is confirmation
that airway constriction has been relieved (PEF > 70% of
predicted value), the patient may be discharged. If no
improvement is observed, the patient should receive the
next step of treatment for moderate or severe symptoms.
Moderate symptoms (moderate attacks)
The patient develops moderate asthma symptoms, such
as dyspnea, at rest, there is a limitation of daily activities
and orthopnea (PEF 50–70% of predicted value).
Treatment Treatment consists of repeated β2-adrenoceptor
agonist inhalation by nebulizer, intravenous aminophylline
by drip infusion, intravenous corticosteroids, subcutaneous
epinephrine and/or oxygen.
Patients with severe symptoms (severe attacks)
Patients with very severe symptoms may be unable to
move and may be forced to assume a bent-forward
posture (orthopnea) because of dyspnea and have 
difficulty in speaking. The PEF may be less than 50% of
personal best value and SpO 2 may be less than 90% 
(PaO 2 < 60 torr).
Treatment Treatment consists of aminophylline con-
tinuous drip, repeated i.v. corticosteroids, repeated
β2-adrenoceptor agonist inhalation by nebulizer, sub-
cutaneous epinephrine and oxygen inhalation.
Very severe symptoms of asthma: emergencies
(very severe attacks)
At this stage, patients cannot speak or move and may show
cyanosis, mental confusion and/or respiratory arrest.
Treatment Treatment consists of the continuation of pre-
vious drug therapy and admission to an intensive care
unit (ICU) with preparation of mechanical ventilation.
RECOGNITION AND UTILIZATION OF
JGL1998
The JGL was first developed in 1993 by the Japanese
Society of Allergology (JSA)7,8 and this guideline was
revised in 1995. In 1998, JGL98 was developed by a
workshop on Asthma Management Guideline supported
by the Ministry of Health and Welfare (MHW) Immunology–
Allergy Project. These JGL were developed under essen-
tially the same understanding of asthma and management
methods as described in the previous section.
Recognition and utilization of the guidelines was sur-
veyed on at least three occasions.
1993 survey
Tsukioka and others performed a survey on the recogni-
tion of JGL1993, which was published July 1993. This
survey was undertaken approximately 6 months after the
publication of JGL1993.27–29
A questionnaire on asthma management was sent to
586 physicians, consisting of specialists authorized by the
JSA and councilors of the society, who were treating
patients with bronchial asthma. Of the total 306 res-
pondents in November I993, 241 replied to questions
relating to adult asthma and 129 responded to questions
relating to childhood asthma (including duplicate replies).
First, 97.4% of respondng JSA physicians knew of
JGL1993 6 months after the release of the guidelines;
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57.8% knew the guidelines for adult asthma only, 21.2%
knew the guidelines for childhood asthma only and
17.0% knew both guidelines. Overall, the evaluation of
JGL1993 for adult and childhood asthma by the physi-
cians was: very good 6.1 and 6.8%, respectively;
appropriate 38.0 and 33.3%, respectively; fairly appro-
priate 52.0 and 52.1% respectively; and inappropriate
3.9 and 3.4%, respectively. This observation showed that
JGL1993 was accepted by most asthma specialists at the
start of their implementation.29
Second, answers regarding the status of diagnosis,
patient education and management of asthma indicated
that the number of patients with severe asthma had
decreased in 1993 for both adults and children com-
pared with 5 years previously,27 despite the increase in the
total number of asthma patients in Japan. Specific IgE
radioallergosorbent test (RAST) measurements were fre-
quently performed instead of skin testing for diagnosis
and eosinophil counts and bronchodilator responses
served as an adjunct to the diagnosis. The usefulness of
peak flow measurements was widely recognized and a
detailed plan for allergen avoidance (house dust) was
often given to patients.
Third, choices regarding treatment were investigated in
the same group of allergists. For acute treatment of
adults, the drugs most commonly selected by these 
physicians were, in increasing order of choice, parenteral
aminophylline, oxygen inhalation, parenteral steroids
and parenteral epinephrine. In the case of schoolchildren
(6–16 years), the drugs most commonly selected were
parenteral aminophylline, inhaled beta-stimulants,
oxygen inhalation, inhaled beta-stimulants + disodium
cromoglycate (DSCG), parenteral steroids. For infants
(less than 5 years of age), drugs used included inhaled
beta-stimulants, parenteral aminophylline, oxygen inhala-
tion, inhaled beta-stimulants + DSCG and parenteral
steroids. For maintenance treatment in adults, the drugs
most commonly selected by physicians were, in increas-
ing order of choice, oral administration of sustained-
release theophylline and inhaled corticosteroids and
DSCG inhalation; for school-children (6–16 years), the
drugs used were DSCG inhalation, oral administration 
of sustained-release theophylline, oral administration 
of antiallergic agent preparation and beta-stimulants
+ DSCG inhalation; for infants, the drugs used were
DSCG inhalation, oral administration of sustained-
release theophylline, oral administration of antiallergic
agent preparation and beta-stimulants + DSCG inhala-
tion. The responses to the questionnaire showed that
different drugs were selected for the treatment of asthma
in adults, schoolchildren and infants.28
1997 survey
This survey30 was intended to investigate the degree of
recognition and utilization of JGL1993/1995 among
members of the JSA (internists and pediatricians) in 
comparison with non-member physicians, focusing on
adult asthma in the JGL.
The recognition, acceptance and utilization of the JGL
was surveyed among physicians who diagnosed
bronchial asthma by both qualitative survey (door-to-
door interview; DDS) and quantitative survey (mail
survey; MS) from July 1996 to late January 1997.
Quantitative MS
The subjects for the quantitative MS were selected from
among internists, respiratory specialists and pediatricians
who were or were not members of the JSA. Question-
naires concerning the acceptance and utilization of the
JGL were mailed to prospective respondents, who were
asked to complete the questionnaire and return it by mail.
For the MS, 2800 physicians were mailed questionnaires
at random. Prospective respondents were asked to com-
plete the questionnaires and return them by mail if they
had diagnosed asthma. A total of 1028 physicians (37%)
responded to the questionnaires; 552 were members of
the JSA, including 388 respiratory specialists, 89
internists and 75 pediatricians. A total of 476 were not
members of the JSA, including 55 respiratory specialists,
390 internists and 31 pediatricians.
Recognition and utilization of the JGL in MS The follow-
ing results are based on the 1028 responses to the
questionnaires sent by mail.
1. Recognition of the JGL. Question: ‘Do you know of
the JGL prepared by the JSA?’
Ninety-four percent of the 552 JSA members who did
diagnose asthma were aware of the JGL, but only 52.8%
of the 476 non-members were aware of it.
2. First impression of the JGL. Question: ‘When you
read the JGL for the first time, how much difference did
you notice from your own previous diagnosis and treat-
ment policies?’
Exactly 45.3% JSA members and 56.8% non-members
who read the JGL found a difference between the guide-
lines and their previous policies.
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3. Utilization of the JGL. Question: ‘Have you used the
JGL as a reference in your diagnosis and treatment of
asthma?’
A total of 83.2% JSA members who were aware of the
JGL used it; similarly, 83.6% JSA non-members used the
JGL.
4. Information sources on asthma management
among JGL readers. Question: ‘What kind of informa-
tion do you consider to be basic to your current diagnosis
and treatment policy for asthma?’
Among physicians who had read the JGL, the JGL itself
and medical journals were the major basis of diagnosis
and treatment policies. The JSA meeting gave informa-
tion for JSA members.
Qualitative DDS
Ten well-trained interviewers (non-medical) visited physi-
cians after confirming both their willingness to participate in
this survey and their having diagnosed asthma. Subjects
were randomly selected from among the members of the
JSA and non-members, including internists, respiratory spe-
cialists and pediatricians. During the first visit, recognition of
the JGL was examined and copies of the JGL were left with
the physicians for the next visit. During the second visit,
information regarding recognition, acceptance and utiliza-
tion of the JGL was gathered both by formulized questions
and by recording the comments of the physicians.
Subjects for survey and participation rate The rate of
participation in the qualitative DDS was 78%. In February
1997, 285 physicians of the JSA were asked by DDS
whether they had treated asthma and 235 replied ‘yes’.
Then, 183 (78%) of these physicians agreed to partici-
pate in the DDS.
Evaluation of the JGL in DDS The following results are
based on the responses of the 127 physicians who were
visited by interviewers. The physicians were given infor-
mation on the JGL 1-2 weeks before the visits. Interviewers
solicited comments on the ease of reading, ease of
understanding, amount of information, appropriateness
of information, clinical usefulness and overall evaluation.
For each of the items, physicians were asked to give their
opinions scores as follows: 1, quite good; 2, good; 3, not
very good; 4, not good at all; and 5, unknown.
Overall evaluation Of the physicians interviewed,
75–91% judged the JGL to be quite good or good. The
overall rate of evaluation of the JGL as ‘very good’ or
‘good’ was 81.7% among JSA members and 92.8%
among non-members. It seems that JSA members were
more critical of the guidelines.
Evaluation points and problems in the JGL in DDS
Interviewers asked the physicians to comment freely on
the JGL and their comments were recorded and cate-
gorized as evaluation points or problems. The major
evaluation points were establishment of the guidelines
themselves and standardization of treatment approach.
Second points were introduction of inhaled corticos-
teroids in step-wise severity dependent treatment systems
and the use of peak flow measurement for the evaluation
of asthma severity. Concerning problems with the guide-
lines, the contents and design of the guidelines were
not easy to discern and more compact guidelines for
non-specialists and generalists were suggested. Other
problems were a lack of clarity regarding the safety of
inhaled corticosteroids and the efficacy of antiallergic
drugs and the position of their use according to the sever-
ity of the asthma.
In this 1997 survey, we found in the MS that 94% of
JSA members who diagnosed asthma were aware of the
guidelines, but only 52% of non-members were aware of
them. Although almost half the JSA member and non-
member physicians who read the guidelines found
differences from their previous policies, once they had
read the JGL most began using it in their treatment of
asthma. These observations show that JGL are accept-
able to most physicians and can be used for asthma
management. In the DDS, we found a similar but slightly
more favorable response to the JGL. Between 80 and
90% of physicians evaluated the JGL as good after they
had read it.
1999 survey
From June to August 1999, a survey on the recognition
and utilization of JGL1998 was undertaken on members
of the JSA and Japanese Society of Pediatric Allergy
(JSPA) and non-member physicians who diagnosed
asthma patients. The total number of JSA/JSPA members
was 1317 (673 internists, 644 pediatricians), while the
total number of non-members was 4646 (2626 inter-
nists, 2020 pediatricians). Interviewers visited physicians
who accepted the interview and recorded their answers.31
Of the JSA/JSPA members, 96% knew the contents of
JGL1998 and only 1% did not. Of the non-members,
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68% knew the contents of JGL1998, 7% did not and the
rest (25%) knew only of the publication of the JGL.
Regarding the utilization of JGL1998 in the treatment of
asthma, of the JSA/JSPA members, 71% used it very
much, 5% pretty used it well and 24% did not use it. Of
non-members, 79% of physicians who knew the JGL used
the JGL very much, while 13% did not.
The first to third choices of antiasthma agents were
surveyed. In chronic adult asthma, the sum of the per-
centage of the first three choices was high for slow-release
theophylline and inhaled corticosteroids. There was no
significant difference in this choice between JSA/JSPA
members and non-members.
In chronic childhood asthma, the first choice was slow-
release theophylline, then followed by inhalation of
DSCG and β2-adrenoceptor agonist. The use of inhaled
corticosteroids increased along with the severity of asthma.
A significant observation of the survey performed in
1999 is that the awareness of JGL increased from 50 
to 70% among non-member physicians, showing the
progress of implementation of asthma management
guidelines.
EFFECT OF IMPLEMENTATION OF JGL
Since the publication of the JGL in 1993 and the Global
Initiative for Asthma (GlNA) in 1995, many of the surveys
on the control of asthma at clinics with asthma specialists
have shown that the number of hospital admissions and
the frequency of emergency room visits due to asthma
exacerbation have decreased.31–34
Fueki et al.31,32 performed a mail survey of their asthma
patients, asking about the frequency of hospital and
emergency room visits due to asthma exacerbation and
reported on the replies of 205 patients. The frequency of
hospitalization and emergency room visits decreased by
70% in 1997 compared with 1993, while the percentage
of patients using inhaled corticosteroids increased from
43 to 52% during the same period. These authors also
performed a mail survey of physicians, internists and
pediatricians (all JSA-authorized specialists) to determine
differences in the management of asthma between 5
years ago and the present time. The most common
response was that the management of asthma had
improved. The major reasons for this answer were
reported to be the development of the JGL, wider use of
inhaled corticosteroids and peak flow monitoring.
Ishihara33 and Koshino34 also reported an improve-
ment of asthma management after the development of
asthma management guidelines and the introduction of
inhaled corticosteroids. In accordance with this view,
there are many reports on the implementation of asthma
management guidelines in the US and Europe.36–38 Non-
compliance with asthma management guidelines was
shown to be associated with increased morbidity and
costs for asthma-related care.36–38 Surveys of generalists
have shown that treatment and diagnostic procedures
were insufficient compared with published asthma man-
agement guidelines (including GlNA), showing that the
treatment procedures given in the guidelines would be
made widely known.36–38 Other studies also report that
compliance with asthma management guidelines has
improved the control of asthma.39,40 These reports in
Japan and other countries show that utilization of asthma
management guidelines improves asthma management
and the implementation of these guidelines by general
practitioners is critical to improving the quality of life of
asthma patients in general. However, it should be noted
that patients whose asthma is still not well controlled by
conventional therapy recommended by the JGL should
be referred to specialists for further evaluation of man-
agement plans.
FUTURE TASKS
These surveys have generated many suggestions for
tasks to be undertaken in the near future, including the
following.
1. Making the asthma management guidelines wide-
ly known among internists and pediatricians, especially
non-members of the JSA. For this purpose, the prepa-
ration of a concise handbook for desk use, which
includes both adult and childhood asthma manage-
ment, is needed.
2. Assisting asthma patients and their families by pro-
viding practical methods for self-management and infor-
mation for their deeper understanding of the disease. At
present, a practical guide to drug inhalation and for the
measurement of PEF is needed.
3. The promotion of research, both clinical and basic,
to provide information for further progress in asthma
management and to investigate the efficacy of the long-
term administration of anti-inflammatory agents (includ-
ing inhaled corticosteroids).
These points should be clarified to ensure progress in
the care of asthma patients. Finally, asthma management
guidelines should be reevaluated regularly and revised
versions should be published regularly and frequently.
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